Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

Nițescu, Maria; Vâjâitu, Cristina; Săndulescu, Oana; Streinu‐Cercel, Adrian; Pițigoi, Daniela; Preoţescu, Liliana; Streinu‐Cercel, Anca

doi:10.1515/rrlm-2017-0030

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Romania, the most prevalent HCV genotype is genotype 1, 93.46% of patients having the genotype 1B (4). Among the eligibility criteria, the level of fibrosis is an important factor (5). Liver biopsy is still considered the gold standard for the staging of fibrosis and the evaluation of necroinflammatory activity, despite its limitations: invasive, it does not allow a dynamic evaluation of fibrosis and life-threatening complications (6,7).…”

Section: Introductionmentioning

confidence: 99%

The influence of hemodialysis on FibroTest parameters

Orășan

Breaban

Stefan

et al. 2019

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Chronic hepatitis C viral infection is an important cause of morbidity and mortality in patients with end-stage renal disease treated with hemodialysis. Liver fibrosis represents a main determinant of liver disease prognosis and clinical management, and its assessment by liver biopsy can decide treatment allocation. Although liver biopsy is the gold standard for staging liver fibrosis, it is an invasive procedure associated with complications that are more prevalent in patients with end-stage renal disease. FibroTest represents a surrogate marker of fibrosis which evaluates the levels of apolipoprotein A1, total bilirubin, haptoglobin, gamma-glutamyltransferase and α2-macroglobulin, generating a score that indicates the level of fibrosis. Discrepancies were observed in clinical practice between FibroTest score and histopathological findings. The aim of this study was to evaluate how hemodialysis influences the level of each FibroTest parameter and the final score. The systematic literature review conducted by us suggests that hemodialysis induces a reduction in apolipoprotein A1, haptoglobin and bilirubin levels, with an increase in gamma-glutamyltransferase and alpha-2-macroglobulin levels. In conclusion, hemodialysis modifies the levels of FibroTest parameters, suggesting that it may also have an impact on the accuracy of liver fibrosis assessment in hemodialysis patients.

show abstract

Section: Introductionmentioning

confidence: 99%

The influence of hemodialysis on FibroTest parameters

Orășan

Breaban

Stefan

et al. 2019

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…A small number of HCV infected patients in Romania were exposed to DAAs, since such regimens were only used there in clinical trials (11), limited studies (12,13) and for the treatment of chronic patients with advanced fibrosis (F3 and F4 scores) (14). A recent autochthonous study showed 100% SVR among subtype 1b chronic Romanian patients undergoing DAAs treatment with ombitasvir/paritaprevir/ritonavir, dasabuvir with and without ribavirin for 12 weeks and that the quantitative regression of liver stiffness was inversely correlated with the duration of the HCV infection (15).…”

Section: Introductionmentioning

confidence: 99%

Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania

Dinu

Țârdei

Ceauşu

et al. 2018

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Background: Severe complications of chronic hepatitis C -i.e. cirrhosis and hepatocellular carcinoma -are important causes of morbidity and mortality worldwide. Despite the overwhelming rates of sustained virologic response achieved after therapy with different combinations of direct-acting antiviral drugs (DAAs), treatment failure is still recorded, and is due to the mutations harboured by hepatitis C virus (HCV) resistance associated variants (RAVs) selected during therapy. Baseline RAVs testing was found significant for guiding treatment in the cases of treatment failure and, sometimes, in naïve patients.Methods: Romanian chronic hepatitis C patients unexposed to DAAs and infected with subtype 1b HCV were studied. Serum samples were used for Sanger population sequencing of a fragment containing NS3 viral protease, known to harbour resistance mutation against protease inhibitors (PIs).Results: Catalytic triad and zinc-binding site in the studied sequences were conserved. Low-intermediate resistance mutations to first generation PIs were detected either alone or in conjunction with resistance substitutions associated with second generation PIs. Cross-resistance and reduced susceptibility to certain DAAs were observed.Discussion: This study focused on HCV patients infected with subtype 1b strains, the most prevalent in Romania. The rate of RAVs found in this work is consistent with the results reported by similar studies from other countries. Noticeably, numerous polymorphisms of unknown significance to DAAs resistance, but reflecting the

show abstract

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

Abstract: Introduction. The past years have revolutionized the treatment of hepatitis C virus (HCV) infection, with high

Cited by 2 publications

References 18 publications

The influence of hemodialysis on FibroTest parameters

The influence of hemodialysis on FibroTest parameters

Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania

Contact Info

Product

Resources

About